Sun Pharma Advanced Research Company (SPARC) has reported results for the fourth quarter (Q4FY26) and year ended March 31, 2026.
The company has reported a net profit at Rs 1,760.70 crore for the quarter under review as compared to a net loss of Rs 60.98 crore for the same quarter in the previous year. The total income of the company has increased by many folds at Rs 1,855.02 crore for Q4FY26 as compared to Rs 27.19 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported a net profit at Rs 1,761.34 crore for the fourth quarter ended March 31, 2026 as compared to a net loss of Rs 59.77 crore for the same quarter in the previous year. The total income of the company increased by many folds at Rs 1,855.02 crore for Q4FY26 as compared to Rs 27.19 crore for the corresponding quarter previous year.
For the year ended March 31, 2026, the company has reported a net profit at Rs 1,552.13 crore as compared to a net loss of Rs 345.22 crore for the previous year. The total income of the company has increased by many folds at Rs 1,890.00 crore for year under review as compared to Rs 73.56 crore for year ended March 31, 2025.
For the year ended March 31, 2026, on the consolidated basis, the company has reported a net profit at Rs 1,553.20 crore as compared to a net loss of Rs 342.51 crore for the previous year. The total income of the company increased by many folds at Rs 1,890.12 crore for year under review as compared to Rs 73.56 crore for year ended March 31, 2025.
